Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression
Homology Medicines, Inc. (FIXX)
Last homology medicines, inc. earnings: 3/12 04:10 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
- Additional Data at ASGCT Annual Meeting Demonstrate Precision of HR-Based Approach with Genome-Wide Integration Assays Confirming On-Target Editing and No Off-Target Events - - New Data from GTx-mAb Platform Support Potential for Targeting Many Complement-Related Disorders - - Further Characterization of Homology’s Naturally Derived AAVHSC Capsids Highlight Their Broad Biodistribution and a Novel Discovery Revealed One Capsid with Low Tropism to the Liver, a Key Functional Benefit for Selecting New Disease Indications - - Homology Symposium to be Held Today, May 18, at 7:30 a.m. ET - BEDFORD, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, unveiled today the mechanism of action (MOA) and optimization of HMI-103, the nuclease-free gene editing candidate currently in a Phase 1 trial for phenylketonuria (PKU). HMI-103 utilizes the body’s natural DNA repair process of homologous recombination (HR) to insert a functiona
Show less
Read more
Impact Snapshot
Event Time:
FIXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FIXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FIXX alerts
High impacting Homology Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
FIXX
News
- Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million [Yahoo! Finance]Yahoo! Finance
- Homology Medicines Declares Distribution to Common StockholdersGlobeNewswire
- Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law FirmGlobeNewswire
- HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXBusiness Wire
- Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases [Yahoo! Finance]Yahoo! Finance
FIXX
Earnings
- 11/14/23 - Miss
FIXX
Sec Filings
- 3/27/24 - Form 8-K
- 3/22/24 - Form 8-K/A
- 3/20/24 - Form 8-K
- FIXX's page on the SEC website